Human EGFR-DEL19/T790M/C797S Stable Cell Line-Ba/F3

Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene, with triple mutations such as Del19/T790M/C797S being particularly associated with resistance to standard therapies like osimertinib. Researchers have been investigating novel strategies to overcome this resistance, including the combination of new drugs. In a recent study, WX-0593, a potent anaplastic lymphoma kinase (ALK) inhibitor, demonstrated a synergistic effect when used alongside EGFR monoclonal antibodies, significantly inhibiting the growth of EGFR triple-mutant cell lines, particularly in Ba/F3 cells harboring the Del19/T790M/C797S mutation. This work highlights the importance of exploring combination therapies in addressing the challenges posed by resistant NSCLC.

Figure 1. The researchers examined the impact of WX-0593 combined with Vectibix on the proliferation of four EGFR triple-mutant cell lines, revealing significant synergy in Ba/F3 cells. (Zheng Q, et al., 2022)

Creative Biogene's Human EGFR-Del19/T790M/C797S Stable Cell Line-Ba/F3 serves as a powerful tool for researchers investigating EGFR resistance mechanisms and testing therapeutic efficacy. These stable cell lines are ideal for in vitro screening and targeted therapy studies, aiding the development of innovative treatment strategies for EGFR-mutant NSCLC.